

**Celadon Pharmaceuticals Plc**  
**("Celadon", the "Group" or the "Company")**

**Finance Update**

**London, 31 January 2025** - Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines, wishes to provide an update on its financial position.

The Company announced on 2 January 2025 that it had received £897k from its £1m draw down request, under its Committed Credit Facility. The Company is therefore due a further £103k. Following correspondence with the Committed Credit Facility provider (the "Lender") the Company now expects this payment during February 2025.

The Company has sufficient working capital up to March 2025, regardless of the outstanding payment, assuming expected cash receipts from customers and the support of creditors.

As previously announced, the Company continues to explore alternative lending facilities to the Committed Credit Facility. The Company can confirm it is no longer in discussions with the finance provider referred to in its announcement on 18 November 2024. The Company is however progressing discussions with other providers and will make further updates as and when appropriate.

The Company also announces that its registered office address has been updated to 71-75 Shelton Street, London, WC2H 9JQ, following the sale of the previous registered office premises by the landlord. This change ensures continuity in compliance with statutory requirements.

**Enquiries:**

**Celadon Pharmaceuticals Plc**  
James Short

Via Canaccord Genuity Limited

**Canaccord Genuity Limited (Nominated Adviser and Broker)**  
Bobbie Hilliam / Andrew Potts

+44 (0)20 7523 8000

**Global Investment Strategy UK Limited (Joint Broker)**  
James Sheehan

+44 (0)20 7048 9400

**About Celadon Pharmaceuticals Plc**

Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation, proprietary GMP extraction and an analytical and R&D laboratory. Celadon's Home Office licence allows for the commercial supply of its pharmaceutical-grade cannabis product. The Group owns an approved clinical trial using cannabis-based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics, which is developing a licensed cannabinoid medicine to treat children with Autism Spectrum Disorder.

For further information please visit our website [www.celadonpharma.com](http://www.celadonpharma.com)

This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication of this announcement, this information is now considered to be in the public domain.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

UPDFLFALLIIVIE